ROIVRoivant Sciences Ltd.
Pharmaceutical Preparations
- Revenue
- $8M
- 72% YoY
- Operating margin
- -6235.7%
- 81% YoY
- EBITDA
- −$512M
- 48% YoY
- Market cap
- —
- Employees
- —
- Net debt / EBITDA
- —
- −$937M net debt
- AI in 10-K
- —
Red flags 1 of 9
- TSR below peersClear—3+ of last 5 years
- High CEO pay despite TSRClear—Median CEO pay ≥ $15M and TSR flag
- Active 13DClear0 filingsActive-intent 13D in 18 months
- Net insider sellingClear$0 netNet sales over $10M in 12 months
- Earnings not backed by cashClear—Cash flow under 80% of net income
- Dilutive SBCFired42× of revenueOver 10% of revenue
- Payouts exceed cash flowClear-172% of cash flowBuybacks + dividends over cash flow
- Goodwill-heavyClear—Over 40% of assets
- Shareholder dissentClear—Any vote under 80% support
Financials
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 | YoY |
|---|---|---|---|---|---|---|
| Revenue | $55M | $32M | $33M | $29M | $8M | 72% |
| Operating income | −$1.4B | −$907M | $4.5B | −$1.0B | −$515M | 49% |
| Net income | −$845M | −$1.0B | $4.3B | −$172M | −$300M | 74% |
| Operating cash flow | −$678M | −$843M | −$765M | −$839M | −$750M | 11% |
| Capex | $17M | $13M | $1M | $5M | $8M | 78% |
| Stock-based comp | $565M | $218M | $200M | $289M | $346M | 20% |
| Buybacks | — | $0 | $0 | $1.3B | — |
Deal filings
None.
13D filers
None on file.
Insider trading
- Open-market buys, 12 mo
- $0 · 0
- Open-market sells, 12 mo
- $106M · 14
- Net
- −$106M
Pay vs performance
| Year | CEO total comp | Comp actually paid | TSR (indexed) | Peer TSR |
|---|---|---|---|---|
| FY2026 | $3M | $382M | 561 | 145 |
| FY2025 | $163M | $120M | 204 | 104 |
| FY2024 | $738K | $46M | 213 | 108 |
| FY2023 | $49M | $98M | 149 | 100 |